Recurrent Ovarian Carcinoma Active Not Recruiting Phase 1 / 2 Trials for Olaparib (DB09074)

IndicationStatusPhase
DBCOND0030000 (Recurrent Ovarian Carcinoma)Active Not Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02208375mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianTreatment
NCT01116648Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast CancerTreatment